BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee R, Ramchandran K, Sanft T, Von Roenn J. Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer. Annals of Oncology 2015;26:1838-45. [DOI: 10.1093/annonc/mdv207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Santero M, Pérez-Bracchiglione J, Acosta-Dighero R, Meade AG, Antequera A, Auladell-Rispau A, Quintana MJ, Requeijo C, Rodríguez-Grijalva G, Salas-Gama K, Dorantes-Romandia R, Salazar J, Solà I, Urrútia G, Bonfill Cosp X. Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews. BMC Cancer 2021;21:712. [PMID: 34134661 DOI: 10.1186/s12885-021-08330-5] [Reference Citation Analysis]
2 Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivelä TT. Metastatic uveal melanoma: The final frontier. Prog Retin Eye Res 2022;:101041. [PMID: 34999237 DOI: 10.1016/j.preteyeres.2022.101041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Haun MW, Estel S, Rücker G, Friederich HC, Villalobos M, Thomas M, Hartmann M. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017;6:CD011129. [PMID: 28603881 DOI: 10.1002/14651858.CD011129.pub2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 96] [Article Influence: 15.8] [Reference Citation Analysis]
4 Rantala ES, Hernberg MM, Lundin M, Lundin J, Kivelä TT. Metastatic uveal melanoma managed with best supportive care. Acta Oncol 2021;60:135-9. [PMID: 32960119 DOI: 10.1080/0284186X.2020.1817978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Zhang Q, Zhang L, Yu J, Li H, He S, Tang W, Zuo J, Lu W. Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold. RSC Adv 2017;7:26060-9. [DOI: 10.1039/c7ra04261b] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Woo SM, Joo J, Kim SY, Park SJ, Han SS, Kim TH, Koh YH, Chung SH, Kim YH, Moon H, Hong EK, Lee WJ. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology. 2016;16:1099-1105. [PMID: 27618657 DOI: 10.1016/j.pan.2016.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
7 Usborne CM, Mullard AP. A review of systemic anticancer therapy in disease palliation. British Medical Bulletin 2018;125:43-53. [DOI: 10.1093/bmb/ldx045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Olver I, Keefe D, Herrstedt J, Warr D, Roila F, Ripamonti CI. Supportive care in cancer—a MASCC perspective. Support Care Cancer 2020;28:3467-75. [DOI: 10.1007/s00520-020-05447-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
9 Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383-2396. [PMID: 28648400 DOI: 10.1016/s0140-6736(17)31462-9] [Cited by in Crossref: 323] [Cited by in F6Publishing: 207] [Article Influence: 64.6] [Reference Citation Analysis]